Evidence map›Paper›PMID 34321050›Full record

ArticleChinese medicine2021

Shenzhi Jiannao formula ameliorates vascular dementia in vivo and in vitro by inhibition glutamate neurotoxicity via promoting clathrin-mediated endocytosis.

Danfeng Tian, Yangyang Guo, Dandan Zhang, Qiang Gao, Ganlu Liu, Jingfeng Lin, Ze Chang, Yuchun Wang, Rui Su, Zhenyun Han

Open access · goldAbstract read
In one paragraph

Article in Chinese medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Journal of ginseng research · 2023
    Review
  7. Adenosine AMolecules (Basel, Switzerland) · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Danfeng TianBeijing University of Chinese Medicine, Beijing, 100029, China.
Yangyang GuoBeijing University of Chinese Medicine, Beijing, 100029, China.
Dandan ZhangBeijing University of Chinese Medicine, Beijing, 100029, China.
Qiang GaoBeijing University of Chinese Medicine, Beijing, 100029, China.
Ganlu LiuBeijing University of Chinese Medicine, Beijing, 100029, China.
Jingfeng LinBeijing University of Chinese Medicine, Beijing, 100029, China.
Ze ChangBeijing University of Chinese Medicine, Beijing, 100029, China.
Yuchun WangBeijing University of Chinese Medicine, Beijing, 100029, China.
Rui SuDepartment of Scientific Research, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
Zhenyun HanShenzhen Hospital of Beijing University of Chinese Medicine (Longgang), No. 1 Dayun Road, Longgang District, Shenzhen, 518172, China. tohanzhenyun@126.com.ORCID http://orcid.org/0000-0002-6831-2364
Beijing University of Chinese Medicine · CNCapital Medical University · CN

Funding

National Natural Science Foundation of China 81673910
6 · The paper itself

Abstract

backgroundSynaptic damage and glutamate excitotoxicity have been implicated in the pathogenesis of vascular dementia (VD). Clathrin, RAB5B and N-methyl-D-aspartic acid receptor 1 (NMDAR1) proteins play a vital role in endocytosis of synaptic vesicles in neurons and glutamate over accumulation. Previous researches have been confirmed that Shenzhi Jiannao (SZJN) formula has an anti-apoptotic and neuroprotective effect in VD, but the underlying mechanisms are still unclear. In this study, we aimed to explore the effect of SZJN formula on cognitive impairment and glutamate excitotoxicity via clathrin-mediated endocytosis (CME) in vivo and in vitro.

methodsSZJN formula consists of Panax ginseng C.A.Mey., Anemarrhena asphodeloides Bunge, and Paeonia anomala subsp. veitchii (Lynch) D.Y.Hong & K.Y.Pan. All herbs were prepared into granules. Both common carotid arteries were permanent occluded (2-vessel occlusion, 2VO) in male Sprague Dawley (SD) rats to model VD. One day after operation, the rats began daily treatment with SZJN formula for 2 weeks. The neuroprotective effects of SZJN formula was subsequently assessed by the novel object recognition test, Morris water maze, hematoxylin-eosin (HE) staining and Nissl staining. Glutamate cytotoxicity was assessed by detecting cell viability and cell death of PC12 cells. Immunohistochemistry, immunofluorescence, Western blot, and quantitative real-time PCR were used to detect the expression levels of clathrin, RAB5B, and NMDAR1.

resultsAdministration of SZJN formula effectively improved short-term memory and spatial memory. SZJN formula treatment significantly reduced hippocampal neuronal loss, and recovered the arrangement and morphology of neurons and Nissl bodies. Moreover, SZJN formula promoted the proliferation of PC12 cells and inhibited glutamate-induced cell death. The down-regulation of clathrin and RAB5B, as well as the upregulation of NMDAR1 in the brain induced by 2VO or glutamate was also notably reversed by SZJN formula at both the protein and mRNA levels, which may contribute to SZJN formula induced improved neurological function.

conclusionsTaken together, our findings provide evidence that the neuroprotective effects of SZJN formula in experimental VD maybe mediated through promoting the expression of clathrin-mediated endocytosis and reducing NMDARs-associated glutamate excitotoxicity. SZJN formula serves as a promising alternative therapy and may be a useful herbal medicine for preventing progression of VD.

Indexed as

Clathrin-mediated endocytosisCognition recoveryGlutamateNeurotoxicityShenzhi Jiannao formulaVascular dementia

Identifiers

PMID34321050
PMCPMC8317332
OpenAlexW3134118458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.